We recently spoke to Jayakrishna Ambati, co-founder of Inflammasome Therapeutics, who along with his colleagues, is exploring how Kamuvudines – molecules that inhibit the inflammatory behavior of the innate immune system – can help prevent retinal degradation associated with geographic atrophy. This week, we also have stories on off-the-shelf cell therapies, a food-inspired drug delivery approach, and the mobile platform, mVacciNation, that is helping to coordinate COVID-19 vaccine distribution across Africa.
Weekly Spotlight

Constant advancements in monoclonal antibody engineering technology are driving breakthrough therapeutic approaches for patients who need them the most. Download Thermo Fisher Scientific’s infographic to learn more about the history, common development challenges, and key workflow considerations of monoclonal antibody therapeutics.

More Information
 
DRUG DISCOVERY
Putting the Brakes on Inflammation
05/12/2021 | Maryam Mahdi
How can we prevent the retinal degradation caused by geographic atrophy?
ADVANCED MEDICINE
Cell Therapy on Demand
05/11/2021 | Jo Brewer
Is pharma making progress in the development of off-the-shelf cell therapies?
DRUG DELIVERY
Food for Thought
05/11/2021 | Maryam Mahdi
Drawing pharmaceutical inspiration from Russian cuisine.
BUSINESS PRACTICE
Digital Coordination
05/12/2021 | Maryam Mahdi
mVaccination is a mobile platform transforming COVID-19 vaccine distribution.
 
White Papers
Top five ways of improving the stability of your formulation

Formulation development is a critical activity for many industries, from pharmaceuticals, to paints and coatings. Read more
Exploring the rigor and requirements of Analytical Quality by Design

Analytical QbD (AQbD) promises to extend the rigor and benefits of QbD into the area of analytical method development. Read more
 
Special Promotions
Manufacturing Strategies for mRNA Vaccines and Therapeutics

mRNA has emerged as the promising modality for a wide range of therapeutics and vaccines. This technology will not only revolutionize the field of vaccine development by allowing a rapid response to disease outbreaks, it will also help to address diseases with gene therapy approaches or cancer treatments. Learn more with our White Paper.
Experience speed, sensitivity, and accuracy in your antibody screening

Learn how the ZE5 Cell Analyzer can actualize high- throughput with automation-ready robotic features, collect data using multiple lasers and detectors, enabling more complex and informative multiplex analysis, and identify rare therapeutic antibodies with desired characteristics in functional and screening assays. Learn more
Innovation in the Consumer Health Industries

Catalent Consumer Health brings innovation and experience to multiple product categories including over-the-counter pharmaceuticals, nutritional supplements, and the beauty industry. Learn more
New Podcast: Unlocking Digitalization with eData Exchange

We chat with Stephen Wing from Merck about eData Exchange and how it can be used to improve your ability to share and use electronic data seamlessly – key concepts when implementing new digital technologies. Listen now
Overcoming Challenges in Vaccine Development

Learn about vaccine development history, common challenges researchers face, how to hit key milestones in your research, and what to consider at each stage of the workflow in this unique infographic. Find out more
 
Must-See Events Worldwide

We work with event organizers from all around the world to help bring the pharma industry together, from large congresses to intimate meetings that fit around a table. Discover some of the events that we partner with and and stay up-to-date with the latest developments.
Find out more
This email was sent to {~email~} by info@themedicinemaker.com. To ensure delivery of emails to your inbox, please add info@themedicinemaker.com to your address book or safe sender list. To view online, please click here.

Create or manage your account here
Unsubscribe here

The Medicine Maker is a brand of Texere Publishing Limited (trading as Conexiant)

Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.